We offer our registered users tailored information, free online courses and exclusive content.
Our platform has been renewed. All users registered at any of the old websites are kindly requested to reset their password. Why is this?
... or you lost your password?
Thyroid disorders are among the most commons encountered in the endocrinological practice. In the Colorado study (US), 9.4% of subjects had high TSH concentration, with higher frequency found in women than in men. There is no unanimity of opinion among specialists regarding the need for thyroid screening, or in the approach to treatment of hypothyroidism, especially whether or not subclinical hypothyroidism should be treated. Also, there is still controversy if women who desire pregnancy should be screened for thyroid diseases and whether or not they should be treated in borderline situations.
Thyroid nodules are common, with an estimated prevalence ranging from 3% to 7% on the basis of palpation. From 20% to 48% of patients with one palpable thyroid nodule are found to have additional nodules when investigated by ultrasound.
The American Cancer Society estimates that thyroid cancer incidence is increasing by approximately 6% per year. Scientific thyroid societies over the world have updated their recommendations for the evaluation and management of thyroid disorders, nodules and cancer, and these topics will be addressed
This conference, hosted by Serono Symposia International Foundation, will represent a unique opportunity to confront different experiences from several well-recognized experts in Europe. The main objective of the meeting will be to critically review recently published international guidelines in thyroid disorders and to address potential controversies in daily practice.
After attending this conference, participants will have up-to-date knowledge on thyroid diseases and will be able to:
Serono Symposia International Foundation (www.seronosymposia.org) is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net
The Conference “International guidelines in thyroid disease in daily practice” (June 8-9, 2012, Vienna, Austria) is designated for a maximum of 9 (nine) hours of European CME credits (ECMEC). Each medical specialist should claim only those credits that he/she actually spent in the educational activity. EACCME credits are recognized by the American Medical Association (AMA) towards the Physician’s Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, please contact the AMA.
Learning effectiveness project
Serono Symposia International Foundation is conducting a Learning Effectiveness Project at meetings during 2012. The meeting 'International guidelines in thyroid disease has been chosen to participate in this project.
Friday, June 8
Session I: Hyperthyroidism / thyroid autoimmunity
Session Chairman: G J Kahaly, Germany
14.30 L1: Genetics vs. environment in autoimmune thyroid disease
T Bednarczuk, Poland
15.00 L2: TSH receptor autoantibodies: Differentiation and clinical relevance
P D Olivo, USA
15.30 L3: Guidelines for the management of Graves‘ hyperthyroidism
R Bahn, USA
16.30 L4: Consensus management of Graves‘ orbitopathy
L Bartalena, Italy
17.00 L5: Cardiac involvement in Graves’ vs. nonautoimmune hyperthyroidism
B Biondi, Italy
17.30 L6: Thyroid autoimmunity and pregnancy
K Poppe, Belgium Video presentation
Saturday, June 9
Session II Hypothyroidism / Thyroid nodules
Session Chairman: A Pinchera, Italy
09.00 L7: New guidelines for the management of thyroid dysfunction during pregnancy
J H Lazarus, United Kingdom Video presentation
09.30 L8: Cardiovascular risks of subclinical hypothyroidism
S Pearce, United Kingdom
10.00 L9: New European guidelines for the treatment of hypothyroidism
B Nygaard, Denmark
11.00 L10: Guidelines for diagnosis of thyroid nodules
P Vitti, Italy
11.30 L11: Guidelines for the treatment of thyroid nodules
J L Wemeau, France
12.00 L12: New treatment modalities of thyroid nodules
L Hegedus, Denmark
Session III Thyroid cancer
Session Chairman: J Orgiazzi, France
14.00 L13: Surgery for thyroid cancer: State of the Art
H Dralle, Germany
14.30 L14: Management of differentiated thyroid cancer
S Leboulleux ,France
15.00 L15: Management of medullary thyroid cancer
B Jarzab, Poland
16.00 L16: Ultrasonography guidelines for the follow-up of thyroid cancer
L Leenhardt, France
16.30 L17: Management of metastatic / poor prognosis forms of thyroid cancer / new targeted therapies
L Groussin, France
17.00 L18: Pitfalls: Interesting cases of differentiated thyroid cancer
M Alevizaki, Greece
Luigi Bartalena
Department of Clinical and Experimental Medicine
University of Insubria
Varese, Italy
George J. Kahaly
Department of Medicine I
Gutenberg University Medical Center
Mainz, Germany
Jacques Orgiazzi
Service d’endocrinologie-diabétologie-maladies métaboliques
Hospices Civils de Lyon
Centre hospitalier Lyon-Sud, Université Lyon 1
Pierre-Bénite, France
Simon Pearce
Institute of Human Genetics
International Centre for Life
Newcastle upon Tyne, UK
Serono Symposia International Foundation adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME) and all other professional organizations, as applicable, which state that programs awarding continuing education credits must be balanced, independent, objective, and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices, and other products (other than those uses indicated in approved product labeling/package insert for the product) may be presented in the program (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so participants may form their own judgments, based on full disclosure of the facts. Further all opinions and recommendations presented during the program and all program-related materials neither imply an endorsement, nor a recommendation, on the part of Serono Symposia International Foundation. All presentations solely represent the independent views of the presenters/authors.The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:
Maria Alevizaki: Declared no potential conflict of interest
Rebecca S. Bahn: Declared no potential conflict of interest
Luigi Bartalena: Declared his presentation includes discussion of the potential use of rituximab for Graves’ orbitopathy.
Sabina Baumgartner-Parzer: Declared no potential conflict of interest
Bernadette Biondi: Declared no potential conflict of interest
Tomasz Bednarczuk: Declared no potential conflict of interest
Henning Dralle: Declared no potential conflict of interest
Lionel Groussin: Declared no potential conflict of interest
Laszlo Hegedüs: Declared receipt of honoraria from Genzyme, Novo Nordisk and Theraction. Declared to be member of Genzyme, Novo Nordisk and Theraction advisory boards and to be a stakeholder in Theraction
Barbara Jarzab: Declared receipt of consultation fees from Astra Zeneca and to be member of the Astra Zeneca advisory board
George J. Kahaly: Declared no potential conflict of interest
John H. Lazarus: Declared no potential conflict of interest
Sophie Leboulleux: Declared receipt of honoraria from Genzyme
Laurence Leenhardt: Declared no potential conflict of interest
Birte Nygaard: Declared no potential conflict of interest
Paul D. Olivo: Declared to be an employee of Quidel corporation
Jacques Orgiazzi: Declared receipt of honoraria from Merck Serono
Simon H.S. Pearce: Declared to be member of GSK advisory board and of Merck-Serono ETA-2011, Krakow
Aldo Pinchera: Declared no potential conflict of interest
Kris Poppe: Declared receipt of honorariafrom Merck-Serono ETA-2011, Krakow
Paolo Vitti: Declared no potential conflict of interest
Jean Luis Wémeau: Declared no potential conflict of interest
